Loading clinical trials...
Loading clinical trials...
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas
Conditions
Interventions
Irinotecan Liposomal Injection
Oxaliplatin
+4 more
Locations
200
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Banner Health- MD Anderson Cancer Center
Gilbert, Arizona, United States
Mayo Clinic - Scottsdale
Phoenix, Arizona, United States
Comprehensive Blood And Cancer Center
Bakersfield, California, United States
University of California- Irvine Health Cancer Cente
Costa Mesa, California, United States
City of Hope National Medical Center
Duarte, California, United States
Start Date
February 11, 2020
Primary Completion Date
July 23, 2022
Completion Date
February 18, 2025
Last Updated
April 20, 2026
NCT06225999
NCT01654861
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions